Previous Article | Next Article 
Infect Immun, May 1998, p. 2272-2278, Vol. 66, No. 5
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Potential of a Novel Protein, OMP26, from
Nontypeable Haemophilus influenzae To Enhance Pulmonary
Clearance in a Rat Model
Jennelle M.
Kyd* and
Allan W.
Cripps
School of Human and Biomedical Sciences,
Faculty of Applied Science, University of Canberra, Belconnen,
Australian Capital Territory 2616, Australia
Received 5 August 1997/Returned for modification 31 October
1997/Accepted 20 February 1998
 |
ABSTRACT |
A major outer membrane protein band of approximately 25 to 27 kDa
is commonly observed in strains of Haemophilus influenzae. This study has investigated the potential of a 26-kDa protein (OMP26)
from nontypeable H. influenzae (NTHI) as a vaccine
candidate. OMP26 was used to immunize rats via intestinal Peyer's
patches, followed by an intratracheal boost. Immunization was found to significantly enhance bacterial clearance following pulmonary challenge
with both the homologous NTHI strain and a different NTHI strain.
Significant levels of anti-OMP26 were found in the serum and
bronchoalveolar lavage from immunized rats, and isotypes of
immunoglobulin G (IgG) were also measured in serum. Analysis of IgG
isotypes present in serum following OMP26-immunization suggest that
predominantly a T-helper 1-type response was induced. The OMP26 protein
was amino-terminally sequenced and found to have no homology with the
P5 of H. influenzae type b P5 or the fimbrin protein of
NTHI, both can migrate upon sodium dodecyl sulfate-polyacrylamide
gel electrophoresis at similar molecular masses but OMP26 has 100%
homology with a segment of the H. influenzae Rd genome. The
results of this study suggest that OMP26 may be a suitable vaccine
candidate against NTHI infection and warrants continued investigation
and characterization.
 |
INTRODUCTION |
Nontypeable Haemophilus
influenzae (NTHI) is a gram-negative bacterium that is a common
cause of otitis media (2, 23), pneumonia (3, 25),
exacerbation of chronic bronchitis (reviewed in reference
23), sinusitis (13, 33), meningitis,
postpartum and neonatal infections (27, 35), osteomyelitis,
septicemia, bacteremia, and other invasive bacterial diseases (reviewed
in references 23 and 31).
Currently, there is no vaccine available that can prevent the
occurrence of these NTHI infections.
Several outer membrane proteins (OMP) have been assessed as potential
vaccine candidates. The OMP P6 is highly conserved among strains
(26). Immunization studies with recombinant P6 in a mixture
of other proteins failed to protect chinchillas against otitis media
(10); however, mucosal immunization with P6 resulted in
enhanced pulmonary clearance in rats that differed in rate among
strains of NTHI (16). The major porin protein from NTHI, P2
has significant variability in surface loop regions between strains
(6, 11, 20). Mucosal immunization with P2 resulted in
significant pulmonary clearance in rats (15); however, the degree of clearance was dependent on the specificity of the T- and
B-cell responses to the P2 protein and was less than the clearance reported previously following immunization with P6 (16).
A major OMP corresponding to the classified P5 band at approximately 26 kDa (non-heat modified) has been investigated in H. influenzae type b (Hib) (22) and, more recently, NTHI
(5). This OMP was one of two lower-molecular-mass bands on
sodium dodecyl sulfate (SDS)-polyacrylamide gels used to subtype
H. influenzae strains (1) and has an apparent
molecular mass of 25 to 27 kDa. The protein, when purified from a Hib
strain (21), was found to be heat modifiable, demonstrating
an apparent molecular mass of 35 kDa after heating for 30 min at
100°C in the presence of
-mercaptoethanol. A fimbrin protein of a
similar molecular mass and expressed by NTHI has been characterized
(28) and found to have 92% amino acid sequence homology
with the Hib P5 and the same heat-modifiable characteristic. The NTHI
fimbrin was capable of conferring partial protection against NTHI in a
chinchilla otitis media model (28).
This study was undertaken to characterize and assess the potential of
another 26-kDa OMP, called OMP26. The results demonstrate that this
protein enhanced pulmonary clearance of both homologous and
heterologous strains of NTHI and suggest that OMP26 warrants further
investigation as a potential vaccine candidate. (OMP26 is the subject
of an international patent [15a].)
(Part of this study was presented at the 8th International Congress of
Mucosal Immunology, 17 to 20 July 1995, San Diego, Calif.)
 |
MATERIALS AND METHODS |
Bacterial strain and culture.
NTHI strains of biotype I
(NTHI-I; isolate 289) and biotype II (NTHI-II) were isolated from the
sputum of adult patients with chronic bronchitis. HI-CD was obtained
from the Swiss Serum and Vaccine Institute, Berne, Switzerland, as an
NTHI strain; however, it was positive (unpublished data) for the
cap gene following hybridization using the pU038 probe
(14). Hib-II (biotype II) was isolated from the sputum of a
chronic bronchitic. The bacteria were prepared by overnight growth at
37°C in 5% CO2 on brain heart infusion agar plates
supplemented with 50 ml of defibrinated horse blood per liter of agar
(Hunter AntiSera, Callaghan, New South Wales, Australia).
Purification of OMP26.
A crude outer membrane preparation
was obtained (24) from bacteria grown overnight on agar
plates, and OMP26 was purified by preparative polyacrylamide gel
electrophoresis (PAGE) as previously described (17).
Preparative SDS-PAGE to purify OMP26 was performed with a Bio-Rad model
491 Prep Cell, using a 60-ml 14% T-1.42% C acrylamide-BIS
(N,N'-methylenebisacrylamide) separating gel with
a 10-ml 4% T-0.36% C acrylamide-BIS stacking gel polymerized in a
37-mm (internal diameter) column (17). Fractions were
concentrated by lyophilization and analyzed for protein content by
analytical SDS-PAGE. OMP26 isolated under these conditions contained
SDS, which was subsequently removed (29). Fractions
containing OMP26 were pooled and dialyzed prior to determination of
protein concentration. The presence of lipooligosaccharide (LOS) was
assessed by both silver staining of SDS-PAGE minigels and assaying with
the E-TOXATE Limulus lysate test (Sigma, Castle Hill, New
South Wales, Australia).
Analytical SDS-PAGE.
A 10-µl fraction sample of purified
OMP26 was added to an equal volume of sample buffer containing SDS and
-mercaptoethanol and boiled for 5 min. Electrophoresis was performed
with minigels of a gradient of 10 to 15%, using the Pharmacia
PhastSystem followed by silver staining using the PhastSystem staining
unit.
Protein concentration determination.
Protein concentration
was determined with the Pierce Micro BCA (bicinchoninic acid) protein
assay reagent and the Pierce albumin standard (Laboratory Supplies,
Marrickville, New South Wales, Australia).
Immunization.
Specific-pathogen-free DA male rats aged
between 8 and 10 weeks were used, immunized, and challenged as
previously described (16). The immunization protein was
prepared by emulsifying 200 or 800 µg of protein per ml in a 1:1
ratio of incomplete Freund's adjuvant (IFA; Difco Laboratories,
Detroit, Mich.), and phosphate-buffered saline (PBS), and a total
inoculum of 10 or 40 µg of protein, respectively, was administered to
each animal via subserosal injection of intestinal Peyer's patches
(IPP). Control groups included (i) a sham-immunized group receiving IFA
and PBS only and (ii) a positive group immunized with killed bacteria
of the homologous NTHI strain. Bacteria were killed by suspension in
1% (wt/vol) paraformaldehyde in PBS and incubated at 37°C for 2 h. The bacteria were washed four times in PBS, and the concentration
was adjusted to a bacterial equivalent of 2 × 1010
per ml. Killing was verified, and bacteria were then emulsified in a
1:1 ratio with IFA so that each animal received approximately 5 × 108 bacteria. Rats received an intratracheal (i.t.) boost
on day 14 post-IPP immunization. The animals were sedated with
halothane, and 10 µg of OMP26 at a concentration of 200 µg per ml
in PBS was introduced into the lungs via an i.t. cannula and dispersed with two 5-ml volumes of air. The nonimmune group received 50 µl of
PBS, while the killed bacterium-immunized group received 50 µl of
killed bacteria (bacteria count of 1010 per ml).
Bacterial challenge.
Bacteria were prepared by overnight
culture as described above and resuspended in PBS. The concentration of
inoculum was estimated by optical density at 405 nm and confirmed by
counting CFU of the overnight plating of serial dilutions of the
inoculum.
Pulmonary challenge with live bacteria was performed on day 21 post-IPP
immunization. The animals were sedated with halothane, and a bolus
inoculum of 5 × 108 CFU of live H. influenzae in 50 µl of PBS was introduced into the lungs via an
i.t. cannula and dispersed with two 5-ml volumes of air. Four hours
after lung inoculation, animals were killed by an intraperitoneal
injection of pentobarbital sodium. Blood was collected by heart
puncture, and aliquots of serum stored at
20°C for antibody
analysis. Lungs were lavaged with five 2-ml volumes of PBS via the
trachea, which had been exposed through an incision in the neck, and
the pooled bronchoalveolar lavage (BAL) was serially diluted to
determine CFU. Lungs were also removed following lavage and homogenized
in 10 ml of PBS, and bacterial counts were determined.
Cytospin and BAL cell counts.
Cytospin slides (Shandon Inc.,
Pittsburgh, Pa.) were prepared to determine percentages of
polymorphonuclear neutrophils, macrophages, and others cells present in
the BAL. Percentages were determined from three differential cell
counts on each slide, and mean percentages ± standard errors of
the means (SEM) were calculated. The BAL was centrifuged, the pellet
was resuspended in PBS, and the total number of cells present in the
BAL was determined by using a hemocytometer and staining with methylene
blue.
Antigen-specific ELISAs.
Polysorb microtiter wells (Nunc,
Roskilde, Denmark) were coated with purified OMP26 in 100 µl of
coating buffer (15 mM Na2CO3, 35 mM
NaHCO3 [pH 9.6]) overnight at 4°C. The concentrations
of OMP26 were 1 µg per ml for assay of immunoglobulin G (IgG), IgG2a, IgA, and IgM and 10 µg per ml for IgG1, IgG2b, IgG2c, and IgE. The
plates were washed five times in washing buffer (PBS containing 0.05%
Tween 20). The wells were blocked with 100 µl of blocking buffer (5%
skim milk in PBS-0.05% Tween 20) for 60 min at room temperature.
Plates were washed five times, and serum (1/10 to 1/3,200) or BAL (1/2
to 1/16) samples were serially diluted in blocking buffer, added to the
wells, and incubated at room temperature for 90 min. After removal of
the samples by washing five times, 100 µl of horseradish
peroxidase-conjugated anti-rat immunoglobulin diluted in blocking
buffer was added to the wells and incubated at room temperature for 90 min. Conjugated immunoglobulins used were goat anti-rat IgG (1/2,000),
IgA (1/1,000), and IgM (1/4,000) (Fc specific; Nordic Immunological
Laboratories, Tilberg, Netherlands); and mouse anti-rat IgG1 (1/500),
IgG2a (1/1,000), IgG2b (1/500), and IgG2c (1/500) (ICN Biochemicals
Inc., Costa Mesa, Calif.). The plates were washed five times, and the
wells were developed with 100 µl of the substrate
tetramethylbenzidine (Fluka, Buchs, Switzerland) in phosphate citrate
buffer (pH 5) containing 0.05% (vol/vol) H2O2.
The reaction was stopped with 100 µl of 0.5 M H2SO4. Plates were read at 450 nm on a Titertek
Multiscan MCC/340 plate reader. Plate background was determined by rows
coated with coating buffer alone and treated the same as test wells.
Between-plate variation was assessed by comparison of one immune and
one control sample repeated on each plate. Serum or BAL was diluted
until an optical density reading in a range between 0.4 and 0.9 was obtained. The enzyme-linked immunosorbent assay (ELISA) titer was
calculated by multiplying the reciprocal of the dilution factor by the
optical density value.
Antigen-specific lymphocyte assay.
The assay was performed
essentially as described previously (7, 17). Briefly,
lymphocytes from mesenteric lymph nodes were resuspended in culture
medium (Multicel RPMI 1640 [Cytosystem, Castle Hill, New South Wales,
Australia] containing 0.01 M HEPES [pH 7.2], 5 × 10
5 M
-mercaptoethanol, 2 mM L-glutamine
[ICN, Sydney, Australia], 5% fetal calf serum, and
penicillin-streptomycin-amphotericin B [as described above]) to
obtain a final concentration of 106 cells per ml. The
antigen (OMP26) or bacterial extract prepared as described elsewhere
(17) was suspended in culture medium in a 10-fold dilution
series and sterile filtered. The cell suspension and antigen were added
in triplicate to flat-bottom multiwell microculture plates (Nunc) to
give a final volume of 0.2 ml per well. Lymphocyte proliferation was
estimated by [3H]thymidine (Amersham Australia, North
Ryde, New South Wales, Australia) incorporation for the last 8 h
of a 4-day culture. Results were calculated by subtraction of
background from the geometric means of triplicate wells and then the
geometric mean ± SEM of the entire treatment group.
Immunoblot assay.
Proteins were separated by SDS-PAGE and
electrophoretically transferred to nitrocellulose (0.2-µm pore size;
Bio-Rad Laboratories, North Ryde, NSW, Australia) (30) for
55 min in 25 mM Tris-192 mM glycine (pH 8.8) buffer. Membranes were
soaked in Tris-buffered saline (TBS; 20 mM Tris, 500 mM NaCl [pH
7.5]) for 10 min, blocked for 30 min with TBS containing 5% (wt/vol)
skim milk, washed twice (5 min) in TTBS (TBS, 0.05% Tween [pH 7.5]),
and incubated at room temperature for 90 min in rat serum diluted
10-fold in TTBS-5% (wt/vol) skim milk. After washing, the membrane
was incubated for 90 min with goat horseradish peroxidase-conjugated
anti-rat IgG (Fc specific; Nordic Immunology) diluted 1/500 in
TTBS-5% skim milk. Before development with 0.05% (wt/vol)
4-chloro-1-naphthol (Bio-Rad Laboratories)-16.7% (vol/vol)
methanol-0.015% (vol/vol) H2O2 in TBS, the
membrane was washed twice in TTBS and once in TBS.
Electron microscopy.
Immunoelectron microscopy with goat
anti-rat immunoglobulin bound to 12-nm gold spheres was used to
determine if OMP26 was surface exposed. Bacteria from strain NTHI-I
were washed and suspended in distilled water (approximately
109 CFU/ml), loaded onto nickel grids, and incubated at
room temperature for 60 min. The grids were rinsed for 15 s in
PBS, blocked by incubation for 1 h with 0.5% (wt/vol) bovine
serum albumin in PBS, and then incubated for 1 h with 1:10
dilution of rat antiserum. After washing, the grids were incubated for
1 h with 12-nm colloidal gold conjugated goat anti-rat IgG
(Pierce, Rockford, Ill.) diluted 1:40, washed, negatively stained, and
viewed by an electron microscope technical expert on a Philips electron
microscope (at the John Curtin School of Medical Research, Canberra,
Australian Capital Territory, Australia).
Preparation of OMP26 for amino acid sequencing.
OMP26 was
prepared for amino (N)-terminal sequencing by SDS-PAGE, using a Protean
II electrophoresis unit (Bio-Rad) and a 12% acrylamide resolving gel.
The protein was then transferred to polyvinylidene difluoride (PVDF)
membrane (Millipore, Bedford, Mass.), using a TransBlot (Bio-Rad). The
location of the protein band on the PVDF membrane was determined by
Coomassie staining, and the PVDF membrane was destained with methanol
following excision of the protein section. This was sequenced by
Cortecs International, Deeside, Clwyd, United Kingdom.
Statistical analysis.
The data have been expressed as
means ± SEM. The pulmonary clearance data, total numbers of
phagocytic cells, and differential cell count data were compared for
statistical significance between groups by one-way analysis of
variance, followed by Tukey's test for multiple-comparison analysis
(Macintosh Systat). Antibody data were assessed for between-group
significance by an unpaired t test, and lymphocyte
proliferation data were assessed by a fully factorial analysis of
variance (Macintosh Systat). Linear correlation between two variables
was determined using the Pearson correlation coefficient (Macintosh
Systat).
 |
RESULTS |
Purification of OMP26.
OMP26 was successfully separated from a
group of three proteins with molecular masses of between 26 and 30 kDa.
Figure 1 shows the position of this
protein in relation to the other two, and the silver-stained gel
indicates the high degree of purity following the final purification
step. Assessment of the heat-modifiable characteristic of this protein
found that after 30 min, the boiled protein sample still migrated with
the same molecular mass (Fig. 1), as did the other neighboring protein
bands. This indicated that none of the three proteins in the molecular
mass range of 26 to 30 kDa obtained in the semipurified extraction was
likely to be the heat-modifiable P5 or fimbrin proteins. Assessment of the protein for the presence of LOS contamination was performed with a
E-TOXATE assay kit and found to be less than 0.6 µg of endotoxin per
mg of protein. This represented the detection limit of the assay
and is substantially less than LOS contamination reported in
other immunization studies with proteins (10).

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 1.
SDS-PAGE analysis of OMP26 and two other proteins with
higher molecular masses. Proteins were separated on a 12%
acrylamide-BIS gel by SDS-PAGE. Lane 1, molecular mass standards
(molecular masses shown in kilodaltons on the left). Lanes 2 and 3, the
protein samples were mixed with SDS reducing buffer but were not
boiled. Lane 2, purified OMP26; lane 3, mixed protein sample of the
three main proteins isolated in this molecular weight range. Lanes 4 and 5, same samples as in lanes 2 and 3, respectively, but heated for
30 min at 100°C in SDS reducing buffer containing
-mercaptoethanol.
|
|
Amino acid sequence identification.
An N-terminal amino acid
sequence was obtained from the protein band transferred to a PVDF
membrane. Amino acid sequence analysis for the first 25 peptides is
shown in Fig. 2A. The sequence analysis indicates no sequence homology with the N-terminal sequence of either
Hib P5 (22) or the fimbrin protein (28), which
have similar molecular masses if not heat modified. The N-terminal amino acid sequence does show 100% homology with a segment of the
recently sequenced H. influenzae Rd genome (9),
56% homology with a 21.4-kDa protein from Pasteurella
multocida (18), and 44% sequence homology with a
19-kDa outer membrane protein from Yersinia
pseudotuberculosis (32).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
(A) N-terminal sequence of the first 25 amino acid
residues of OMP26. (B) Comparison of the amino acid sequences of OMP26
and the proteins from H. influenzae Rd genome, P. multocida, and Y. pseudotuberculosis. The shaded areas
represent identical amino acids.
|
|
Polyclonal antisera against OMP26 immunolabeled a surface epitope on
NTHI-I (Fig.
3A) which was not seen
following incubation
of NTHI-I with nonimmune serum (Fig.
3B). These
results suggest
that OMP26 has at least one surface-exposed domain and
that following
mucosal immunization with OMP26, some antibody is
directed against
this region.

View larger version (71K):
[in this window]
[in a new window]
|
FIG. 3.
Electron microscopy view of an NTHI-I strain
immunolabeled with nonimmune rat serum (A) and polyclonal anti-OMP26
rat serum (B) and detected with anti-rat IgG-conjugated gold spheres.
Gold spheres associated with NTHI-I immunolabeled with nonimmune serum
were equivalent to the background, nonspecific binding of the
gold-labeled conjugate, whereas there was consistent labeling above
background binding to NTHI-I immunolabeled with the polyclonal
anti-OMP26 serum (B).
|
|
Bacterial clearance.
Rats immunized with OMP26 and challenged
with live bacteria of the NTHI-I homologous strain on day 21 showed
significant bacterial clearance (P < 0.005). Rats
immunized and boosted with 10 µg of OMP26 had significantly fewer
bacteria in the lung than the nonimmune group after 4 h. Rats
receiving 40 µg of OMP26 in the IPP immunization and boosted with 10 µg of OMP26 had slightly further enhanced bacterial clearance which
was equivalent to the clearance observed for killed-bacteria-immunized
rats (Fig. 4).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
NTHI-I bacteria recovered in the BAL 4 h after
challenge with live bacteria. Nonimmune rats (n = 8)
were sham treated, 10-µg OMP26 group was IPP immunized and i.t.
boosted with 10 µg of OMP26 (n = 7), 40-µg OMP26
group was IPP immunized with 40 µg of OMP26 and i.t. boosted with 10 µg of OMP26 (n = 4), NTHI-I group was IPP immunized
and i.t. boosted with killed bacteria (n = 5). *,
P < 0.005 compared to nonimmune group. Live bacteria
inoculum contained 7 × 109 CFU per ml as determined
by plating of serial dilution.
|
|
Rats immunized with OMP26 and challenged with bacteria from a second
nontypeable strain, NTHI-II (Table
1),
exhibited clearance
of this strain similar to the clearance for the
homologous challenge
and significantly different from that for the
nonimmune rats (
P < 0.005).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Pulmonary clearance and phagocytic cell counts following
mucosal immunization with OMP26 and challenge by homologous and
nonhomologous NTHI strains
|
|
Greater numbers of phagocytic cells were present in the BAL of
OMP26-immunized animals and correlated with the enhanced bacterial
clearance in these animals (Table
1), although differential cell
counts
for polymorphonuclear neutrophils and macrophages were
the same for
immune and nonimmune groups (data not shown).
OMP26-specific immune responses.
Antibody to OMP26 was
measured in the serum and BAL samples of rats immunized with OMP26 as
well as from rats that had been immunized with killed bacteria from
four different strains of H. influenzae. High OMP26-specific
antibody titers for IgG, IgA, and IgM were found in the serum, and for
IgG and IgA in the BAL, of rats immunized with OMP26, with the highest
levels observed for the group receiving the higher immunization dosage
of 40 µg (Table 2). Low levels of
OMP26-specific IgG, IgA, and IgM in the serum and IgG and IgA in the
BAL were also found in rats that had been immunized with different
strains of H. influenzae (Table 2). OMP26-specific IgE could
not be detected (data not shown).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison of OMP26-specific antibodies in serum and BAL
following immunization with either OMP26 or killed bacteria from
H. influenzae strains
|
|
OMP26-specific IgG1 was detectable only following the 40-µg
immunization, whereas IgG2a and IgG2b subclasses were found for
both
10- and 40-µg OMP26 immunization groups (Fig.
5). Levels
of both IgG2a and IgG2b
increased significantly (
P < 0.05) with
the increase
in concentration of OMP26 from 10 to 40 µg in the
IPP inoculum. IgG2c
was also measured; however, significant levels
of OMP26-specific
antibody from this subclass could not be detected
(data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
OMP26-specific levels of IgG subclasses in serum samples
of rats immunized with OMP26. (A) IgG1 antibody; (B) IgG2a antibody;
(C) IgG2b antibody. Values represent means ± SEM for serum from
four to seven rats per group. *, P < 0.05 compared
to nonimmune group.
|
|
Recognition of OMP26 by antibodies present in the serum of
OMP26-immunized and
H. influenzae (four strains)-immunized
rats
was shown by immunoblot analysis (data not shown). There was no
recognition of OMP26 by nonimmune serum.
Cells from the OMP26-immunized group responded significantly to OMP26,
extracts from strains NTHI-I, NTHI-II, and HI-CD, but
not the extract
from the Hib-II strain, in culture in vitro (Fig.
6).

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 6.
Antigen-specific proliferation of lymphocytes isolated
from the mesenteric lymph nodes of OMP26-immunized and nonimmune rats.
Cells were cultured for 4 days with either OMP26 or OMP extract from
four different H. influenzae strains. Shown are lymphocyte
responses to culture with OMP26 (A), NTHI-I OMP extract (B), NTHI-II
OMP extract (C), HI-CD OMP extract (D), and Hib-II OMP extract (E).
Values represent means ± SEM of combined responses for
lymphocytes from four rats per group and triplicate cultures of
lymphocytes per rat. *, P < 0.05 compared to
nonimmune response.
|
|
 |
DISCUSSION |
This study has identified a protein from strain NTHI-I
that is different from the heat-modifiable P5 from Hib and fimbrin protein from NTHI but has a corresponding molecular mass. OMP26 was the
lower-molecular-mass band on SDS-PAGE of a group of three proteins with
molecular masses of between 26 and 30 kDa and corresponded to a major
protein band between P6 and a band corresponding to P4, the next major
OMP for H. influenzae strains. Studies of P5 in Hib strains
had identified P5 as being heat modifiable when boiled for 30 min under
reducing conditions, shifting from an apparent molecular mass of 25 to
27 kDa to one of 35 to 36.5 kDa (21). OMP26 isolated from
NTHI-I was not heat modifiable. N-terminal sequence analysis of OMP26
identified the sequence of this 26-kDa protein as distinctly different
from those of the Hib P5 (22) and a fimbrin protein
(28).
The N-terminal sequence had 100% homology with a segment of the
H. influenzae Rd genome (9) encoding a protein
nominated as an export factor homolog (HI 0916) based on apparent
homology to other skp transporter proteins (76%
similarity). A protein band corresponding to OMP26 was present in all
strains of H. influenzae used in this study (data not
shown). The sequence has a high homology with that reported for the
H. influenzae Rd genome (9), with variation that
resulted in an alteration of amino acids 102 and 170 (unpublished
data).
The sequence for OMP26 had similarities to those of the proteins from
two other gram-negative bacteria, P. multocida and Y. pseudotuberculosis. skp-encoded proteins are believed to play a
role either as chaperones in extracytoplasmic compartments or as
folding catalysts (19). In P. multocida, the
skp gene and the firA gene are part of an operon
governing the first steps of lipid A synthesis (4). In the
H. influenzae Rd genome (9), the location on the
gene encoding OMP26 is also adjacent to the region homologous to the
firA gene. The relationship of OMP26 to these proteins and
any role of OMP26 in protein transport have yet to be determined.
Primary inoculation of OMP26 into the IPP followed by a boost in the
lungs induced immune responses that were highly protective against not
only pulmonary challenge by the homologous strain but also from
challenge by a different unrelated NTHI strain. This immunization
targets the mucosal immune system and has been shown to be effective in
inducing an effective immune response in the lungs (15, 16,
34). Immunization with whole bacteria results in an immune
response to a range of antigens (12) including P2, P6, and
LOS (our unpublished data) and is sufficient to enhance bacterial
clearance of the homologous NTHI strain (34). Immunization with P2 (15), the most abundant OMP, did not result in
bacterial clearance of this magnitude; however, immunization with P6
enhanced pulmonary clearance to a similar degree in some strains
(16). Immunization with OMP26 resulted in clearance similar
to that for whole-bacterium immunization, suggesting that OMP26
may be a suitable vaccine candidate.
OMP26-specific antibody levels were measured in serum and BAL from
OMP26-immunized rats and from rats immunized with killed bacteria from
four H. influenzae strains. Significant titers of IgG, IgA,
and IgM were found in OMP26-immunized serum, and these levels increased
with an increase in concentration of OMP26 in the IPP inoculum. Low
levels of OMP26-specific IgG, IgA, and IgM were also found in serum
from whole-bacterium-immunized rats. The levels were lower than in the
purified-protein-immunized rats but were similar in magnitude for the
different H. influenzae strains. OMP26-specific
immunoglobulin in BAL was significant for IgG and IgA in
OMP26-immunized groups but barely detectable in
whole-bacterium-immunized groups. This finding suggests that immunization with killed bacteria results in a poor immune response to
OMP26.
Antigen-specific T-helper (Th)-induced secretion of lymphokines during
antigen processing is believed to influence IgG isotypes (8), and measurement of isotypes of IgG is indicative of the type of Th response induced during immunization. OMP26-specific IgG1
was detected only after immunization with 40 µg of OMP26, suggesting
that this was not the predominant isotype induced. OMP26-specific IgG2a
and IgG2b were detectable, with IgG2a appearing to be the dominant
isotype. These isotype responses suggest that the Th and lymphokine
response following immunization with OMP26 may be a Th1 type response.
Lymphocytes from OMP26-immunized rats proliferated in vitro in response
to OMP26 and OMP extracts from H. influenzae strains. This
finding demonstrates the cross-reactivity of the lymphocytes to T-cell
epitopes in antigen in the different extracts. The magnitude of
response by the OMP26-specific lymphocytes to the OMP extracts was
significantly less than that observed for the purified protein since
OMP26 is present as a small percentage of the total protein concentration in the extracts.
The identification of this 26-kDa protein, called OMP26, as having the
capacity to enhance bacterial clearance following mucosal immunization
has been an important finding. OMP26 may have significant potential as
a candidate for a vaccine against respiratory infections caused by
NTHI. Future studies will be undertaken to further characterize this
protein by the development of clones, determine the degree of
conservation at a molecular level, and identify its role on the
bacterial surface.
 |
ACKNOWLEDGMENTS |
This research was supported by the National Health and Medical
Research Council, Australia, and by Cortecs International. J. Kyd was
supported for part of the study by an Australian Postgraduate Research
Award.
We thank Melissa Musicka for excellent microbiology assistance and
Katherine Gillespie at the John Curtin School of Medical Research for
the electron microscopy work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Faculty of
Applied Science, University of Canberra, P.O. Box 1, Belconnen ACT
2616, Australia. Phone: 61 6 201 2160. Fax: 61 6 201 5402. E-mail:
kyd{at}science.canberra.edu.au.
Editor: J. R. McGhee
 |
REFERENCES |
| 1.
|
Barenkamp, S. J.,
R. S. Munson, Jr., and D. M. Granoff.
1981.
Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles.
J. Infect. Dis.
143:668-676[Medline].
|
| 2.
|
Bluestone, C. D., and J. O. Klein.
1983.
Otitis media with effusion, atelectasis and eustachian tube dysfunction, p. 356.
In
C. D. Bluestone, and S. E. Stool (ed.), Pediatric otolaryngology. The W. B. Saunders Co., Philadelphia, Pa.
|
| 3.
|
Claesson, B. A.,
T. Lagergard, and B. Trollfors.
1991.
Antibody response to outer membrane of noncapsulated Haemophilus influenzae isolated from the nasopharynx of children with pneumonia.
Pediatr. Infect. Dis. J.
10:104-108[Medline].
|
| 4.
|
Delamarche, C.,
F. Manoha,
G. Behar,
R. Houlgatte,
U. Hellman, and H. Wroblewski.
1995.
Characterisation of the Pasteurella multocida skp and firA genes.
Gene
161:39-43[Medline].
|
| 5.
|
Duim, B.,
L. D. Bowler,
P. P. Eijk,
H. M. Jansen,
J. Dankert, and L. van Alphen.
1997.
Molecular variation in the major outer membrane protein P5 gene of nonencapsulated Haemophilus influenzae during chronic infections.
Infect. Immun.
65:1351-1356[Abstract].
|
| 6.
|
Duim, B.,
J. Dankert,
H. M. Jansen, and L. van Alphen.
1993.
Genetic analysis of the diversity in outer membrane P2 of non-encapsulated Haemophilus influenzae.
Microb. Pathog.
14:451-462[Medline].
|
| 7.
|
Dunkley, M. L., and A. J. Husband.
1986.
The induction and migration of antigen-specific helper cells for IgA responses in the intestine.
Immunology
57:379-385[Medline].
|
| 8.
|
Finkelman, F. D.,
J. Holmes,
I. M. Katona,
J. J. F. Urban,
M. P. Beckmann,
L. S. Park,
K. A. Schooley,
R. L. Coffman,
T. R. Mosmann, and W. E. Paul.
1990.
Lymphokine control of in vivo immunoglobulin isotype selection.
Annu. Rev. Immunol.
8:303-333[Medline].
|
| 9.
|
Fleischmann, R. D.,
M. D. Adams,
O. White,
R. A. Clayton,
E. F. Kirkness,
A. R. Kerlavage,
C. J. Bult,
J.-F. Tomb,
B. A. Dougherty,
J. M. Merrick,
K. McKenney, et al.
1995.
Whole-genome random sequencing and assembly of Haemophilus influenzae Rd.
Science
269:496-512[Abstract/Free Full Text].
|
| 10.
|
Green, B. A.,
M. E. Vazquez,
G. W. Zlotnick,
G. Quigley-Reape,
J. D. Swarts,
I. Green,
J. L. Cowell,
C. D. Bluestone, and W. J. Doyle.
1993.
Evaluation of mixtures of purified Haemophilus influenzae outer membrane proteins in protection against challenge with nontypeable H. influenzae in the chinchilla otitis media model.
Infect. Immun.
61:1950-1957[Abstract/Free Full Text].
|
| 11.
|
Haase, E. M.,
A. A. Campagnari,
J. Sarwar,
M. Shero,
M. Wirth,
C. U. Cumming, and T. F. Murphy.
1991.
Strain-specific and immunodominant surface epitopes of the P2 porin protein of nontypeable Haemophilus influenzae.
Infect. Immun.
59:1278-1284[Abstract/Free Full Text].
|
| 12.
|
Hansen, E. J.,
D. A. Hart,
J. L. McGehee, and G. B. Toews.
1988.
Immune enhancement of pulmonary clearance of nontypeable Haemophilus influenzae.
Infect. Immun.
56:182-190[Abstract/Free Full Text].
|
| 13.
|
Hirschmann, J. V., and E. D. Everett.
1979.
Haemophilus influenzae infections in adults: report of nine cases and a review of the literature.
Medicine (Baltimore)
58:80-94[Medline].
|
| 14.
|
Kroll, J. S., and E. R. Moxon.
1988.
Capsulation and gene copy number at the cap locus of Haemophilus influenzae type b.
J. Bacteriol.
170:859-864[Abstract/Free Full Text].
|
| 15.
|
Kyd, J. M., and A. W. Cripps.
1996.
Modulation of antigen-specific T and B cell responses influence bacterial clearance of nontypeable Haemophilus influenzae from the lung in a rat model.
Vaccine
14:1471-1478[Medline].
|
| 15a.
| Kyd, J. M., A. W. Cripps, C. Smith, and Cortecs
International Ltd. 1996. Patent PCT/GB96/01549. Novel
Haemophilus influenzae antigen.
|
| 16.
|
Kyd, J. M.,
M. L. Dunkley, and A. W. Cripps.
1995.
Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model.
Infect. Immun.
63:2931-2940[Abstract].
|
| 17.
|
Kyd, J. M.,
D. Taylor, and A. W. Cripps.
1994.
Conservation of immune responses to proteins isolated by preparative polyacrylamide gel electrophoresis from the outer membrane of nontypeable Haemophilus influenzae.
Infect. Immun.
62:5652-5658[Abstract/Free Full Text].
|
| 18.
|
Manoha, F.,
G. Behar,
R. Houlgarre,
U. Hellman,
H. Wroblewski, and C. Delamarche.
1993.
In
skp protein-Pasteurella multocida.
EMBL data library, EMBL, Heidelburg, Germany.
|
| 19.
|
Missiakas, D.,
J. M. Betton, and S. Raina.
1996.
New components of protein folding in extracytoplasmic compartments of Escherichia coli surA, fkpA and skp/OmpH.
Mol. Microbiol.
21:871-884[Medline].
|
| 20.
|
Munson, R. S., Jr.,
C. Bailey, and S. Grass.
1989.
Diversity of the outer membrane protein P2 gene from major clones of Haemophilus influenzae type b.
Mol. Microbiol.
3:1797-1803[Medline].
|
| 21.
|
Munson, R. S., Jr., and D. M. Granoff.
1985.
Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae.
Infect. Immun.
49:544-549[Abstract/Free Full Text].
|
| 22.
|
Munson, R. S., Jr.,
S. Grass, and R. West.
1993.
Molecular cloning and sequence of the gene for outer membrane protein P5 of Haemophilus influenzae.
Infect. Immun.
61:4017-4020[Abstract/Free Full Text].
|
| 23.
|
Murphy, T. F., and M. A. Apicella.
1987.
Nontypable Haemophilus influenzae: a review of clinical aspects, surface antigens, and the immune response to infection.
Rev. Infect. Dis.
9:1-15[Medline].
|
| 24.
|
Murphy, T. F., and L. C. Bartos.
1988.
Purification and analysis with monoclonal antibodies of P2, the major outer membrane protein of nontypeable Haemophilus influenzae.
Infect. Immun.
56:1084-1089[Abstract/Free Full Text].
|
| 25.
|
Musher, D. M.,
K. R. Kubitschek,
J. Crennan, and R. E. Baughn.
1983.
Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae.
Ann. Intern. Med.
99:444-450.
|
| 26.
|
Nelson, M. B.,
R. S. Munson, Jr.,
M. A. Apicella,
D. J. Sikkema,
J. P. Molleston, and T. F. Murphy.
1991.
Molecular conservation of the P6 outer membrane among strains of Haemophilus influenzae: analysis of antigenic determinants, gene sequences, and restriction fragment length polymorphisms.
Infect. Immun.
59:2658-2663[Abstract/Free Full Text].
|
| 27.
|
Quentin, R.,
A. Goudeau,
R. J. Wallace, Jr.,
A. L. Smith,
R. K. Selander, and J. M. Musser.
1990.
Urogenital, maternal and neonatal isolates of Haemophilus influenzae: identification of unusually virulent serologically non-typable clone families and evidence for new Haemophilus species.
J. Gen. Microbiol.
136:1203-1209[Abstract/Free Full Text].
|
| 28.
|
Sirakova, T.,
P. E. Kolattukudy,
D. Murwin,
J. Billy,
E. Leake,
D. Lim,
T. DeMaria, and L. Bakaletz.
1994.
Role of fimbriae expressed by nontypeable Haemophilus influenzae in pathogenesis of and protection against otitis media and relatedness of the fimbrin subunit to outer membrane protein A.
Infect. Immun.
62:2002-2020[Abstract/Free Full Text].
|
| 29.
|
Suzuki, H., and T. Terada.
1988.
Removal of dodecyl sulfate from protein solution.
Anal. Biochem.
172:259-263[Medline].
|
| 30.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4355[Abstract/Free Full Text].
|
| 31.
|
Turk, D. C.
1984.
The pathogenicity to Haemophilus influenzae.
J. Med. Microbiol.
18:1-16[Abstract/Free Full Text].
|
| 32.
|
Vuoria, R.,
L. Hirvas,
R. B. Raybourne,
D. T. Y. Yu, and M. Vaara.
1991.
In
OMPH-Yersinia pseudotuberculosis.
EMBL data library, EMBL, Heidelburg, Germany.
|
| 33.
|
Wald, E. R.,
G. J. Milmoe,
A. D. Bowen,
J. Ledesma-Medina,
N. Salmon, and C. D. Bluestone.
1981.
Acute maxillary sinusitis in children.
N. Engl. J. Med.
304:749-754[Abstract].
|
| 34.
|
Wallace, F. J.,
R. L. Clancy, and A. W. Cripps.
1989.
An animal model demonstration of enhanced clearance of nontypable Haemophilus influenzae from respiratory tract after antigen stimulation of gut-associated lymphoid tissue.
Am. Rev. Respir. Dis.
140:311-316[Medline].
|
| 35.
|
Wallace, R. J., Jr.,
D. M. Musher,
E. J. Septimus,
J. E. McGowan,
F. J. Quinones,
K. Wiss,
P. H. Vance, and P. A. Trier.
1981.
Haemophilus influenzae infections in adults: characterization of strains by serotypes, biotypes, and lactamase production.
J. Infect. Dis.
144:101-106[Medline].
|
Infect Immun, May 1998, p. 2272-2278, Vol. 66, No. 5
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Novotny, L. A., Partida-Sanchez, S., Munson, R. S. Jr., Bakaletz, L. O.
(2008). Differential Uptake and Processing of a Haemophilus influenzae P5-Derived Immunogen by Chinchilla Dendritic Cells. Infect. Immun.
76: 967-977
[Abstract]
[Full Text]
-
Kyd, J. M., Cripps, A. W., Novotny, L. A., Bakaletz, L. O.
(2003). Efficacy of the 26-Kilodalton Outer Membrane Protein and Two P5 Fimbrin-Derived Immunogens To Induce Clearance of Nontypeable Haemophilus influenzae from the Rat Middle Ear and Lungs as Well as from the Chinchilla Middle Ear and Nasopharynx. Infect. Immun.
71: 4691-4699
[Abstract]
[Full Text]
-
Kaur, R., Sharma, A., Majumdar, S., Ganguly, N. K., Chakraborti, A.
(2003). Outer-membrane-protein subtypes of Haemophilus influenzae isolates from North India. J Med Microbiol
52: 693-696
[Abstract]
[Full Text]
-
Thomas, K. L., Leduc, I., Olsen, B., Thomas, C. E., Cameron, D. W., Elkins, C.
(2001). Cloning, Overexpression, Purification, and Immunobiology of an 85-Kilodalton Outer Membrane Protein from Haemophilus ducreyi. Infect. Immun.
69: 4438-4446
[Abstract]
[Full Text]
-
Sethi, S., Murphy, T. F.
(2001). Bacterial Infection in Chronic Obstructive Pulmonary Disease in 2000: a State-of-the-Art Review. Clin. Microbiol. Rev.
14: 336-363
[Abstract]
[Full Text]
-
Webb, D. C., Cripps, A. W.
(1999). Immunization with Recombinant Transferrin Binding Protein B Enhances Clearance of Nontypeable Haemophilus influenzae from the Rat Lung. Infect. Immun.
67: 2138-2144
[Abstract]
[Full Text]
-
El-Adhami, W., Kyd, J. M., Bastin, D. A., Cripps, A. W.
(1999). Characterization of the Gene Encoding a 26-Kilodalton Protein (OMP26) from Nontypeable Haemophilus influenzae and Immune Responses to the Recombinant Protein. Infect. Immun.
67: 1935-1942
[Abstract]
[Full Text]
-
Foxwell, A. R., Kyd, J. M., Cripps, A. W.
(1998). Nontypeable Haemophilus influenzae: Pathogenesis and Prevention. Microbiol. Mol. Biol. Rev.
62: 294-308
[Abstract]
[Full Text]